Bridgeway Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bridgeway Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-42,500	Closed	-$2.63M	–	1510
2022 Q3	$2.63M	Hold	42,500	–	–	0.07%	439
2022 Q2	$3.39M	Buy	42,500 +17,000	+67%	+$1.61M	0.08%	393
2022 Q1	$2.68M	Hold	25,500	–	–	0.05%	496
2021 Q4	$2.75M	Hold	25,500	–	–	0.05%	504
2021 Q3	$2.79M	Hold	25,500	–	–	0.05%	485
2021 Q2	$2.39M	Buy	+25,500	New	+$2.35M	0.04%	554
2015 Q1	–	Sell	-63,700	Closed	-$821K	–	1539
2014 Q4	$821K	Sell	63,700 -20,900	-25%	-$262K	0.02%	851
2014 Q3	$1.04M	Sell	84,600 -250	-0.3%	-$2.9K	0.03%	736
2014 Q2	$1.34M	Buy	84,850 +100	+0.1%	+$1.43K	0.04%	655
2014 Q1	$1.28M	Sell	84,750 -146,650	-63%	-$1.66M	0.04%	655
2013 Q4	$1.76M	Sell	231,400 -14,600	-6%	-$78.7K	0.05%	528
2013 Q3	$824K	Hold	246,000	–	–	0.03%	807
2013 Q2	$605K	Buy	+246,000	New	+$590K	0.02%	867

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bridgeway Capital Management's HZNP Position: Q4 2022 in Review

Bridgeway Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 42,500 shares — an estimated $2.63M sold.

Bridgeway Capital Management first reported a position in HZNP in Q2 2013 and held it in 13 quarters. The position peaked at $3.39M in Q2 2022. 613 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Bridgeway Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Bridgeway Capital Management sold 42,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $2.63M.
Bridgeway Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 13 quarters.
Bridgeway Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.39M in Q2 2022.
613 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Bridgeway Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.